Join Us At SABCS 2021


Agendia will present new data from ongoing clinical research evaluating the MammaPrint and BluePrint genomic tests at the upcoming 2020 San Antonio Breast Cancer Symposium

SABCS 2020 has illustrated the expanding spectrum of clinical utility for Agendia’s MammaPrint and BluePrint, going well beyond the “chemo/no chemo” question, and highlighted by 5 year outcome data from the innovative neoadjuvant NBRST trial, as well as a biomarker analysis of the APHINITY trial. More information below.

Agendia’s activities at SABCS:

 

Product theater with Q&A featuring MINDACT and NBRST updates:

  • Title: Integrating MammaPrint and BluePrint into Pre- and Post-Operative Patient Care
  • Date: Wednesday, December 9 at 10:00 am CST
  • Speaker: William Audeh, MD, Pat Whitworth, MD, David Hicks, MD

Data Highlights

  • Title: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial
    • Authors: Krop, I., et al.
    • Session: Spotlight Poster Discussion 3 | Wednesday, December 9, 2020 | 6:30pm – 7:30pm CST
    • Poster #: PD3-01
  • Title: 5-year outcomes in the NBRST trial: Preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
    • Authors: Whitworth, P., et al.
    • Session: Spotlight Poster Discussion 9 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
    • Poster #: PD9-01.

More Information below.

#IAMHERE

An intimate portrait series that illustrates the essence of 50 people who have been touched by breast cancer – Click here to view campaign.

Virtual Booth

Visit our virtual booth for more information and to speak with a member of our team.


Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification

  • Authors: Whitworth, P., et al.
  • Session: Poster Session 4
  • Poster #: PS4-04

5-year outcomes in the NBRST trial: Preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival

  • Authors: Whitworth, P., et al.
  • Session: Spotlight Poster Discussion 9 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
  • Poster #: PD9-01

Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients

  • Authors: Sharma, D., et al.
  • Session: Poster Session 7
  • Poster #: PS7-68

Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients

  • Authors: Chen, M., et al.
  • Session: Poster Session 7
  • Poster #: PS7-69

Dierential gene expression analysis and clinical utility of MammaPrint and BluePrint in male breast cancer patients

  • Authors: Crozier, J., et al.
  • Session: Poster Session 14
  • Poster #: PS14-11

Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients

  • Authors: Chen, M., et al.
  • Session: Poster Session 7
  • Poster #: PS7-69

Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers

  • Authors: Kaklamani, V.G., et al.
  • Session: Poster Session 18
  • Poster #: PS18-05

BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial

  • Authors: Krop, I., et al.
  • Session: Spotlight Poster Discussion 3 | Wednesday, December 9, 2020 | 6:30pm – 7:30pm CST
  • Poster #: PD3-01

Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens

  • Authors: McKelley, J., et al.
  • Session: Poster Session 6
  • Poster #: PS6-19

The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in patients aged ≥70 years from the population-based observational FOCUS cohort.

  • Authors: Noordhoek, I., et al.
  • Session: Poster Session 6
  • Poster #: PS6-06

The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer

  • Authors: Lee, L., et al.
  • Session: Ongoing Trials Posters
  • Poster #: OT-12-01

MammaPrint and BluePrint as prognostic indicators for elderly patients with early stage breast cancer

  • Authors: Blumencranz, P.W., et al.
  • Session: Poster Session 6
  • Poster #: PS6-41
  • This field is for validation purposes and should be left unchanged.

For the US, Puerto Rico, and South America

Agendia Inc. USA
22 Morgan
Irvine, CA 92618
(888) 321-2732
[email protected]


For outside the Americas

Agendia NV
Radarweg 60
1043 NT Amsterdam
The Netherlands
[email protected]
+31 (0)20 462 1510